Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02512510 · ClinicalTrials.gov registry record · Phase 3

Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Mylan.

Completed
Registry status
Phase 3
Development phase
611
Enrollment target
1
Study location

NCT02512510: Completed Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Mylan.

NCT02512510 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Mylan. The registered enrollment target is 611 participants, roughly in line with the 634-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02512510, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Mylan.

COMPLETED
Registry status
Phase 3
Development phase
611 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.

Interventions

  • DRUG Placebo
  • DRUG TD-4208

Study Locations (1)

South Carolina

  • Palmetto Medical Research Associates L.L.C. - Easley

Trial Details

FieldValue
Enrollment Target 611 participants
Start Date 2015-09
Est. Completion 2016-09
Phase Phase 3
Mylan

22 total trials

What the finished NCT02512510 record still lists

NCT02512510 is an interventional study that assigns participants to a tested intervention. The registered 611 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 634-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target.

The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02512510 reports a single indexed study location in South Carolina.

Frequently Asked Questions

What is clinical trial NCT02512510 about?

NCT02512510 is a clinical study titled "Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.

What is the current status of trial NCT02512510?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 611 participants. The study started on 2015-09. Estimated completion is 2016-09.

What conditions does trial NCT02512510 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).

What interventions are being tested in trial NCT02512510?

The interventions under investigation include: Placebo (DRUG), TD-4208 (DRUG).

Who is sponsoring clinical trial NCT02512510?

This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02512510 being conducted?

This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Obstructive Pulmonary Disease (COPD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02512510's enrollment target sits among peer trials

611 17th of 36 higher than 20 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04224493 · 612 participants · Phase 3

    A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

  • NCT04590326 · 612 participants · Phase 1

    A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • NCT06266416 · 612 participants · NA

    IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)

  • NCT03536312 · 610 participants · NA

    Treatment in Thoracic Aortic Aneurysm: Surgery vs Surveillance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02512510, the US trial registry maintained by the National Library of Medicine. NCT02512510 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.